SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Botulinum Toxin Injections®, Type A

Drug Requested: Botox® (onabotulinumtoxinA)
Chronic Migraine Headache Prophylaxis

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

- **Maximum quantity limits:** 155 units once every 12 weeks
- **Cosmetic indications are EXCLUDED**

NOTE: In treating adult patients for one or more indications, the maximum cumulative dose should not exceed 400 units, in a 3-month interval. In pediatric patients, the total dose should not exceed the lower of 10 units/kg body weight or 340 units, in a 3-month interval

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. **All criteria must be met for approval**. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 12 months

- ❑ Member must be ≥ 18 years of age
- ❑ Member experiences ≥ 15 headache days per month
- ❑ Member experiences headaches which last ≥ 4 hours per day
- ❑ Member must have failed a **2-month** trial of a least one medication from **TWO** different migraine prophylactic classes supported by the American Headache Society/American Academy of Neurology treatment guidelines 2012/2015/2021/2024, Level A and B evidence; ICSI 2013, high quality evidence **(verified by chart notes or pharmacy paid claims)**:
  - ❑ Anticonvulsants (divalproex, valproate, topiramate)
  - ❑ Beta blockers (atenolol, metoprolol, nadolol, propranolol, timolol)
  - ❑ Antidepressants (amitriptyline, venlafaxine)
  - ❑ Angiotensin II receptor blocker (candesartan) ***requires prior authorization***
  - ❑ Injectable CGRP inhibitors (Aimovig®, Emgality®, Ajovy®) or oral CGRP inhibitors indicated for migraine prevention (Qulipta™, Nurtec ODT®) ***requires prior authorization***
- ❑ Member has been evaluated for medication overuse headache (MOH) (defined as headaches occurring greater than or equal to 15 days per month. It develops as a consequence of regular overuse of acute or symptomatic headache medication for more than 3 months)
- ❑ Treatment will include a plan to taper off the offending medication if MOH is diagnosed
- ❑ **Requests for concurrent use of Calcitonin Gene-Related Peptide (CGRP) inhibitors with Botox® (onabotulinumtoxinA) for migraine headache prevention (if applicable):** Member must meet **ALL** the following criteria **(verified by chart notes and/or pharmacy paid claims)**:
  - ❑ Member must have a diagnosis of Chronic or Episodic Migraine Headache and is continuing to experience ≥ 4 migraine headache days per month after receiving therapy with **ALL** the following criteria:
    - ❑ Member must have failed a **2-month** trial of at least one medication from **TWO** different migraine prophylactic classes supported by the American Headache Society/American Academy of Neurology treatment guidelines 2012/2015/2021/2024, Level A and B evidence: ICSI 2013, high quality evidence:
      - ❑ Anticonvulsants (divalproex, valproate, topiramate)
      - ❑ Beta blockers (atenolol, metoprolol, nadolol, propranolol, timolol)
      - ❑ Antidepressants (amitriptyline, venlafaxine)
      - ❑ Angiotensin II receptor blocker (candesartan) ***requires prior authorization***

(Continued on next page)

- ❑ Member must meet **ONE** of the following:
  - ❑ Member has had an inadequate response to a **2-month** trial with an injectable CGRP inhibitor (e.g., Aimovig®, Ajovy®, Emgality®) or an oral CGRP inhibitor indicated for migraine prevention (e.g., Nurtec® ODT, Qulipta™) ***requires prior authorization***
  - ❑ Member has had an inadequate response to a **6-month** trial (2 injection cycles) of Botox® (onabotulinumtoxinA) ***requires prior authorization***

Reauthorization: 12 months. Check below all that apply. **All criteria must be met for approval**. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member has experienced a positive response to therapy, demonstrated by a reduction in headache frequency
- ❑ Use of acute migraine medications (e.g., NSAIDs, triptans) has decreased since the start of Botox®
- ❑ Member continues to be monitored for medication overuse headache (MOH)
- ❑ **Requests for continuation of concurrent use of Calcitonin Gene-Related Peptide (CGRP) inhibitors with Botox® (onabotulinumtoxinA) for migraine headache prevention (if applicable):** Member must meet the following criteria:
  - ❑ Member has experienced further reduction in the overall number of migraine days or reduction in number of severe migraine days per month compared to monotherapy with the initial agent onabotulinumtoxinA (Botox) and a calcitonin gene-related peptide (CGRP) indicated for migraine prevention **(submit documentation)**

❑ **Medication being provided by: Please check applicable box below.**

❑ **Physician's office** **OR** ❑ **Specialty Pharmacy**

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

***Approved by Pharmacy and Therapeutics Committee**: 5/22/2025
REVISED/UPDATED/REFORMATTED: 5/20/2025